Drug Pipeline

Telisotuzumab Vedotin Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
3
Recruiting
1
Phase 3
2
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-03 NCT06568939
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin…		 Trial sites expanded: 64 -> 71 locations
2026-05-14 NCT04830202
Expanded Access to Telisotuzumab Vedotin		 overall status: "Available" → "Temporarily Not Available"
Active Studies by Phase
Phase 3
1
Phase 2
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT04928846 A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab… Non Small Cell Lung Cancer Recruiting
Phase 2
NCT07323641 Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non… Lung Non-Small Cell Carcinoma Recruiting
NCT06568939 A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin… Non-Small Cell Lung Cancer Recruiting
Sponsors Running Telisotuzumab Vedotin Trials
AbbVie (2) Jonsson Comprehensive Cancer Center (1)
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (3) Lung Cancer (2)
Get alerts when Telisotuzumab Vedotin trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free